Figure 8. Multidimensional validation and efficacy evaluation with the core TF, EMT regulator and miRNA. (A) Survival prognosis forest map related to TFAP2A, hsa-miR-655 and ELF3 in patients with OSC. (B) The expression level of ELF3 from ovary cancer samples (red) and normal ovary samples (gray). (C) Validation of ELF3 from the HPA database. (D) The expression level of TFAP2A from ovary cancer samples and normal ovary samples. (E) Validation of TFAP2A from the HPA database.